Cellosaurus logo
expasy logo

Cellosaurus EN (CVCL_2034)

[Text version]
Cell line name EN
Accession CVCL_2034
Resource Identification Initiative To cite this cell line use: EN (RRID:CVCL_2034)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Population: Japanese.
Doubling time: 24.4 hours (PubMed=12581894); ~50-80 hours (DSMZ=ACC-564).
Microsatellite instability: Instable (MSI-low) (PubMed=31068700; Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
Sequence variations
  • Mutation; HGNC; 9588; PTEN; Simple; p.Leu186Valfs (c.556C>CG); Zygosity=Heterozygous (PubMed=20944090).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (PubMed=20944090).
  • Mutation; HGNC; 11355; STAG2; Simple; p.Leu264Pro (c.791T>C); Zygosity=Heterozygous (Cosmic-CLP=1240127; DepMap=ACH-000978).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg273Glnfs (c.817_818insA); Zygosity=Unspecified (PubMed=12581894).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*24:02,26:01
HLA-BB*35:01,54:01
HLA-CC*01:02,03:03
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.78
Native American0
East Asian, North80.75
East Asian, South16.89
South Asian0
European, North0.4
European, South1.18
Disease Endometrial carcinoma (NCIt: C7558)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 50Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=1240127; DSMZ=ACC-564; TKG=TKG 0665

Markers:
AmelogeninX
CSF1PO12,14
D2S133820,25
D3S135816,18
D5S81812,13
D7S82011 (Cosmic-CLP=1240127; TKG=TKG 0665)
11,11.1 (DSMZ=ACC-564)
D8S117915,17
D13S3178,11
D16S53911,12
D18S5114,15
D19S43316,17
D21S1130,34.2
FGA18,19,20
Penta D10,13
Penta E11,17
TH016,9
TPOX8,11
vWA14,17

Run an STR similarity search on this cell line
Web pages https://tcpaportal.org/mclp/
Publications

PubMed=12581894; DOI=10.1016/S0165-4608(02)00673-8
Isaka K., Nishi H., Sagawa Y., Nakada T., Osakabe Y., Serizawa H., Ebihara Y., Takayama M.
Establishment of a new human cell line (EN) with TP53 mutation derived from endometrial carcinoma.
Cancer Genet. Cytogenet. 141:20-25(2003)

PubMed=20944090; DOI=10.1126/scitranslmed.3001538
Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R., Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A., Lord C.J., Ashworth A., Reis-Filho J.S.
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) DSMZ; ACC-564
TKG; TKG 0665
Cell line databases/resources CLO; CLO_0037161
cancercelllines; CVCL_2034
Cell_Model_Passport; SIDM01045
Cosmic-CLP; 1240127
DepMap; ACH-000978
DSMZCellDive; ACC-564
LINCS_LDP; LCL-1495
Biological sample resources BioSample; SAMN03473481
BioSample; SAMN10988280
Chemistry resources GDSC; 1240127
PharmacoDB; EN_334_2019
Encyclopedic resources Wikidata; Q54832304
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM887005
GEO; GSM888074
GEO; GSM1669765
Polymorphism and mutation databases Cosmic; 1576453
Cosmic; 1995393
Cosmic; 2030463
IARC_TP53; 17882
LiGeA; CCLE_777
Progenetix; CVCL_2034
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number33